Literature DB >> 33849913

The Influence of Vitamin D on Mammographic Density: Results from CALGB 70806 (Alliance) a Randomized Clinical Trial.

Marie E Wood1, Heshan Liu2, Elizabeth Storrick2, David Zahrieh2, H Carisa Le-Petross3, Sin-Ho Jung4, Patricia Zekan5, M Margaret Kemeny6, Jayne R Charlamb7, Lili X Wang8, Gary W Unzeitig9, Candace S Johnson10, Judy E Garber11, James R Marshall10, Isabelle Bedrosian3.   

Abstract

Current therapies for breast cancer prevention only prevent estrogen receptor positive (ER+) disease and toxicity limits use of these agents. Vitamin D is a potential prevention therapy for both ER+ and ER- disease and is safe with few side effects. This study evaluates the effect of 1-year of vitamin D supplementation on mammographic density (MD), a biomarker of breast cancer risk in a multicenter randomized controlled trial. Premenopausal women with ≥25% MD and no history of cancer were randomly assigned to 2,000 international units (IU) of vitamin D or placebo orally daily for 1 year. Change in percent MD was evaluated using Cumulus software after all participants completed treatment. Three hundred women enrolled between January 2011 and December 2013 with a mean age of 43 and diverse ethnicity [14% Hispanic, 12% African American (AA)]. Supplementation significantly increased vitamin D levels compared with placebo (14.5 ng/mL vs. -1.6 ng/mL; P < 0.0001) with all participants on the vitamin D arm achieving vitamin D sufficiency at 12 months. Vitamin D was safe and well tolerated. After adjustment for baseline MD, the mean between-arm difference (vitamin D vs. placebo) at 1 year was -0.75 (-0.26, 1.76; P = 0.56). A greater effect was seen for women with ≥50% MD and AA women, although neither reached significance. This randomized controlled trial demonstrated significant improvement in vitamin D levels with 2,000 IU for 1 year, with 100% of supplemented women achieving sufficiency. However, a null effect was seen regarding change in MD for premenopausal women (the primary outcome of the study). PREVENTION RELEVANCE: Current therapies for breast cancer prevention only prevent estrogen receptor positive (ER+) disease and are underutilized due to toxicity and side effects. Vitamin D is a potential prevention therapy for both ER+ and ER- disease and is safe with few side effects. ©2021 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33849913      PMCID: PMC8449513          DOI: 10.1158/1940-6207.CAPR-20-0581

Source DB:  PubMed          Journal:  Cancer Prev Res (Phila)        ISSN: 1940-6215


  73 in total

1.  Vitamin D and breast cancer risk: the NHANES I Epidemiologic follow-up study, 1971-1975 to 1992. National Health and Nutrition Examination Survey.

Authors:  E M John; G G Schwartz; D M Dreon; J Koo
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  1999-05       Impact factor: 4.254

2.  Mammographic densities and breast cancer risk.

Authors:  N F Boyd; G A Lockwood; L J Martin; J A Knight; J W Byng; M J Yaffe; D L Tritchler
Journal:  Breast Dis       Date:  1998-08

3.  Breast density and parenchymal patterns as markers of breast cancer risk: a meta-analysis.

Authors:  Valerie A McCormack; Isabel dos Santos Silva
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2006-06       Impact factor: 4.254

Review 4.  Equivalent anticancer activities of dietary vitamin D and calcitriol in an animal model of breast cancer: importance of mammary CYP27B1 for treatment and prevention.

Authors:  Aruna V Krishnan; Srilatha Swami; David Feldman
Journal:  J Steroid Biochem Mol Biol       Date:  2012-08-23       Impact factor: 4.292

5.  Premenopausal plasma 25-hydroxyvitamin D, mammographic density, and risk of breast cancer.

Authors:  Kimberly A Bertrand; Bernard Rosner; A Heather Eliassen; Susan E Hankinson; Kathryn M Rexrode; Walter Willett; Rulla M Tamimi
Journal:  Breast Cancer Res Treat       Date:  2014-12-28       Impact factor: 4.872

Review 6.  Modeling vitamin D actions in triple negative/basal-like breast cancer.

Authors:  Erika LaPorta; JoEllen Welsh
Journal:  J Steroid Biochem Mol Biol       Date:  2013-11-14       Impact factor: 4.292

Review 7.  The role of vitamin D in reducing cancer risk and progression.

Authors:  David Feldman; Aruna V Krishnan; Srilatha Swami; Edward Giovannucci; Brian J Feldman
Journal:  Nat Rev Cancer       Date:  2014-04-04       Impact factor: 60.716

8.  Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial.

Authors:  Jack Cuzick; Ivana Sestak; John F Forbes; Mitch Dowsett; Jill Knox; Simon Cawthorn; Christobel Saunders; Nicola Roche; Robert E Mansel; Gunter von Minckwitz; Bernardo Bonanni; Tiina Palva; Anthony Howell
Journal:  Lancet       Date:  2013-12-12       Impact factor: 79.321

9.  Determinants of Mammographic Density Change.

Authors:  Shadi Azam; Arvid Sjölander; Mikael Eriksson; Marike Gabrielson; Kamila Czene; Per Hall
Journal:  JNCI Cancer Spectr       Date:  2019-02-04

Review 10.  Factors affecting uptake and adherence to breast cancer chemoprevention: a systematic review and meta-analysis.

Authors:  S G Smith; I Sestak; A Forster; A Partridge; L Side; M S Wolf; R Horne; J Wardle; J Cuzick
Journal:  Ann Oncol       Date:  2015-12-08       Impact factor: 32.976

View more
  1 in total

1.  Cholesterol and Its Derivatives: Multifaceted Players in Breast Cancer Progression.

Authors:  Giorgia Centonze; Dora Natalini; Alessio Piccolantonio; Vincenzo Salemme; Alessandro Morellato; Pietro Arina; Chiara Riganti; Paola Defilippi
Journal:  Front Oncol       Date:  2022-05-26       Impact factor: 5.738

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.